Improving drug discovery with high-content phenotypic screens by systematic selection of reporter cell lines

Nature Biotechnology

Volumn 34, Issue 1, 2016, Pages 70-77

  Kang, Jungseog ^a,b   Hsu, Chien Hsiang ^a,c,d   Wu, Qi ^a   Liu, Shanshan ^a   Coster, Adam D ^a   Posner, Bruce A ^e   Altschuler, Steven J ^a,d   Wu, Lani F ^a,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SHANGHAI   (China)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHEMICAL COMPOUNDS; CLASSIFICATION (OF INFORMATION); LIBRARIES;

CELLULAR RESPONSE; COMPOUND LIBRARIES; DISCRIMINATORY POWER; DRUG DISCOVERY; IMAGING BIOMARKERS; LARGE COMPOUND LIBRARIES; PREDICTION ACCURACY; REPORTER CELL LINE;

DRUG PRODUCTS;

APICIDIN; BIOLOGICAL MARKER; BORTEZOMIB; CAMPTOTHECIN; CARFILZOMIB; CYAN FLUORESCENT PROTEIN; EPOTHILONE B; ETOPOSIDE; EVEROLIMUS; FLUORESCENT DYE; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MCHERRY FLUORESCENT PROTEIN; NATURAL PRODUCT; NOCODAZOLE; NSC 176324; NSC 26113; NSC 318799; NSC 33570; NSC 60785; OXAMFLATIN; PROTEASOME INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

A549 CELL LINE; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; HELA CELL LINE; HUMAN; HUMAN CELL; MEASUREMENT ACCURACY; NATIONAL HEALTH ORGANIZATION; OPTIMAL REPORTER CELL LINE FOR ANNOTATING COMPOUND LIBRARY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; ANIMAL; DRUG DEVELOPMENT; VALIDATION STUDY;

ANIMALS; CELL LINE; DRUG DISCOVERY; HUMANS; PHENOTYPE;

EID: 84953790713     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3419     Document Type: Article

References (55)

1. van 't Veer, L.J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
2. Thomas, R.K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007).
3. Kolch, W. & Pitt, A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 10, 618-629 (2010).
4. Griffin, J.L. & Shockcor, J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 4, 551-561 (2004).
5. Zhang, J., Yang, P.L. & Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009).
6. Kelloff, G.J. & Sigman, C.C. Cancer biomarkers: selecting the right drug for the right patient. Nat. Rev. Drug Discov. 11, 201-214 (2012).
7. Sundberg, S.A. High-throughput and ultra-high-throughput screening: solution- and cell-based approaches. Curr. Opin. Biotechnol. 11, 47-53 (2000).
8. Mayr, L.M. & Bojanic, D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 9, 580-588 (2009).
9. Koehn, F.E. High impact technologies for natural products screening. Prog. Drug Res. 65 175, 177-210 (2008).
10. Lachance, H., Wetzel, S., Kumar, K. & Waldmann, H. Charting, navigating, and populating natural product chemical space for drug discovery. J. Med. Chem. 55, 5989-6001 (2012).
11. Nielsen, T.E. & Schreiber, S.L. Towards the optimal screening collection: a synthesis strategy. Angew. Chem. Int. Ed. Engl. 47, 48-56 (2008).
12. O' Connor, C.J., Beckmann, H.S. & Spring, D.R. Diversity-oriented synthesis: producing chemical tools for dissecting biology. Chem. Soc. Rev. 41, 4444-4456 (2012).
13. Caie, P.D. et al. High-content phenotypic profiling of drug response signatures across distinct cancer cells. Mol. Cancer Ther. 9, 1913-1926 (2010).
14. Klebe, G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today 11, 580-594 (2006).
15. Schneider, G. Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 9, 273-276 (2010).
16. Inglese, J. et al. High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 3, 466-479 (2007).
17. Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5, 100-107 (2009).
18. Wilson, C.J. et al. Identification of a small molecule that induces mitotic arrest using a simplified high-content screening assay and data analysis method. J. Biomol. Screen. 11, 21-28 (2006).
19. Perlman, Z.E. et al. Multidimensional drug profiling by automated microscopy. Science 306, 1194-1198 (2004).
20. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
21. Potts, M.B. et al. Using functional signature ontology (FUSION) to identify mechanisms of action for natural products. Sci. Signal. 6, ra90 (2013).
22. Young, D.W. et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol. 4, 59-68 (2008).
23. MacDonald, M.L. et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2, 329-337 (2006).
24. Houle, D., Govindaraju, D.R. & Omholt, S. Phenomics: the next challenge. Nat. Rev. Genet. 11, 855-866 (2010).
25. Futamura, Y. et al. Morphobase, an encyclopedic cell morphology database, and its use for drug target identification. Chem. Biol. 19, 1620-1630 (2012).
26. King, K.R. et al. A high-throughput microfluidic real-time gene expression living cell array. Lab Chip 7, 77-85 (2007).
27. Stegmaier, K. et al. Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat. Genet. 36, 257-263 (2004).
28. Kawatani, M. et al. Identification of a small-molecule inhibitor of DNA topoisomerase II by proteomic profiling. Chem. Biol. 18, 743-751 (2011).
29. Muroi, M. et al. Application of proteomic profiling based on 2D-DIGE for classification of compounds according to the mechanism of action. Chem. Biol. 17, 460-470 (2010).
30. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007).
31. Feng, Y., Mitchison, T.J., Bender, A., Young, D.W. & Tallarico, J.A. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat. Rev. Drug Discov. 8, 567-578 (2009).
32. Roti, G. & Stegmaier, K. Genetic and proteomic approaches to identify cancer drug targets. Br. J. Cancer 106, 254-261 (2012).
33. Fuchs, F. et al. Clustering phenotype populations by genome-wide RNAi and multiparametric imaging. Mol. Syst. Biol. 6, 370 (2010).
34. Bakal, C., Aach, J., Church, G. & Perrimon, N. Quantitative morphological signatures define local signaling networks regulating cell morphology. Science 316, 1753-1756 (2007).
35. Taylor, D.L. Past, present, and future of high content screening and the field of cellomics. Methods Mol. Biol. 356, 3-18 (2007).
36. Gustafsdottir, S.M. et al. Multiplex cytological profiling assay to measure diverse cellular states. PLoS One 8, e80999 (2013).
37. Wawer, M.J. et al. Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling. Proc. Natl. Acad. Sci. USA 111, 10911-10916 (2014).
38. Cohen, A.A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511-1516 (2008).
39. Loo, L.H., Wu, L.F. & Altschuler, S.J. Image-based multivariate profiling of drug responses from single cells. Nat. Methods 4, 445-453 (2007).
40. Johnson, R.A. & Wichern, D.W. Applied Multivariate Statistical Analysis. 3rd edn. (Prentice Hall, Englewood Cliffs, N.J., 1992).
41. Martin, C.J. et al. Molecular characterization of macbecin as an Hsp90 inhibitor. J. Med. Chem. 51, 2853-2857 (2008).
42. Reddy, P. et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. USA 101, 3921-3926 (2004).
43. Wójcik, C. et al. Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin-fusion degradation pathway substrates in mammalian cells. Mol. Biol. Cell 17, 4606-4618 (2006).
44. Kuhn, D.J. et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110, 3281-3290 (2007).
45. Chen, D., Frezza, M., Schmitt, S., Kanwar, J. & Dou, Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 11, 239-253 (2011).
46. Kim, T.S. et al. Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation. Mol. Biol. Cell 17, 824-833 (2006).
47. Moffat, J.G., Rudolph, J. & Bailey, D. Phenotypic screening in cancer drug discovery-past, present and future. Nat. Rev. Drug Discov. 13, 588-602 (2014).
48. Kangas, J.D., Naik, A.W. & Murphy, R.F. Efficient discovery of responses of proteins to compounds using active learning. BMC Bioinformatics 15, 143 (2014).
49. Sigal, A. et al. Dynamic proteomics in individual human cells uncovers widespread cell-cycle dependence of nuclear proteins. Nat. Methods 3, 525-531 (2006).
50. Schneider, C.A., Rasband, W.S. & Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671-675 (2012).
51. Sugiyama, M. Dimensionality reduction of multimodal labeled data by local fisher discriminant analysis. J. Mach. Learn. Res. 8, 1027-1061 (2007).
52. Schäfer, J. & Strimmer, K. A shrinkage approach to large-scale covariance matrix estimation and implications for functional genomics. Stat. Appl. Genet. Mol. Biol. 4, e32 (2005).
53. Wu, J., Hu, C.P., Gu, Q.H., Li, Y.P. & Song, M. Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharmacol. Sin. 31, 93-101 (2010).
54. Ono, M. et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 3, 465-472 (2004).
55. Chen, M.C. et al. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis. 4, e810 (2013).